Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Afamelanotide (Scenesse) demonstrated a moderate positive effect on skin photosensitivity in individuals with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with its efficacy comparable to inorganic sunscreen; however, organic sunscreens and various oral treatments (e.g., beta-carotene, vitamin C) showed no effect.
• The studies primarily focused on individuals with EPP or XLP, highlighting the relevance of these findings for this population, which experiences skin photosensitivity due to the accumulation of protoporphyrin IX.
• The safety profile of afamelanotide (Scenesse) was noted as favorable; however, specific safety outcomes or adverse effects were not detailed in the study, indicating a lack of comprehensive safety data.
• No significant safety concerns or adverse effects were highlighted in the reviewed studies, particularly concerning individuals with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP).
• The studies focused on individuals with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), demonstrating that afamelanotide effectively improves skin photosensitivity, which is particularly relevant for these populations due to the accumulation of protoporphyrin IX.